Exelixis (EXEL) Competitors $43.62 -0.46 (-1.04%) Closing price 04:00 PM EasternExtended Trading$43.51 -0.11 (-0.24%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL vs. ALNY, BIIB, INCY, UTHR, NBIX, BMRN, EXAS, RGEN, MDGL, and HALOShould you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Exelixis vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Do institutionals & insiders believe in EXEL or ALNY? 85.3% of Exelixis shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.9% of Exelixis shares are owned by insiders. Comparatively, 1.2% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, EXEL or ALNY? Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExelixis$2.17B5.49$521.27M$2.2019.83Alnylam Pharmaceuticals$2.25B18.68-$278.16M-$2.09-154.10 Which has more risk & volatility, EXEL or ALNY? Exelixis has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Is EXEL or ALNY more profitable? Exelixis has a net margin of 27.99% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Exelixis' return on equity of 28.81% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Exelixis27.99% 28.81% 21.94% Alnylam Pharmaceuticals -11.49%-510.31%-6.48% Do analysts prefer EXEL or ALNY? Exelixis presently has a consensus price target of $43.56, indicating a potential downside of 0.15%. Alnylam Pharmaceuticals has a consensus price target of $340.00, indicating a potential upside of 5.57%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exelixis 2 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.52Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.79 Does the media prefer EXEL or ALNY? In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Exelixis. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 23 mentions for Exelixis. Alnylam Pharmaceuticals' average media sentiment score of 1.08 beat Exelixis' score of 1.03 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 15 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryExelixis and Alnylam Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXEL vs. The Competition Export to ExcelMetricExelixisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.02B$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio19.8321.1726.2519.74Price / Sales5.49262.85405.80109.12Price / Cash22.8841.8936.4957.06Price / Book5.557.237.925.37Net Income$521.27M-$55.05M$3.15B$248.34M7 Day Performance-4.59%-0.74%0.95%1.25%1 Month Performance1.89%6.27%5.25%5.41%1 Year Performance96.04%0.19%32.63%18.06% Exelixis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXELExelixis4.7351 of 5 stars$43.62-1.0%$43.56-0.1%+96.2%$12.02B$2.17B19.831,147Positive NewsAnalyst ForecastALNYAlnylam Pharmaceuticals4.2879 of 5 stars$326.09+1.0%$340.00+4.3%+34.2%$42.52B$2.35B-156.022,000Positive NewsAnalyst ForecastBIIBBiogen4.972 of 5 stars$125.59-0.4%$188.48+50.1%-45.8%$18.40B$9.68B12.407,605INCYIncyte4.3603 of 5 stars$68.10-0.4%$74.53+9.4%+12.3%$13.18B$4.24B212.822,617UTHRUnited Therapeutics4.9948 of 5 stars$287.35+1.1%$386.15+34.4%-9.8%$12.96B$2.88B11.471,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.9153 of 5 stars$125.69+0.2%$162.00+28.9%-8.7%$12.44B$2.36B42.611,800Positive NewsBMRNBioMarin Pharmaceutical4.944 of 5 stars$54.97-0.4%$93.45+70.0%-33.2%$10.54B$2.85B20.443,040EXASExact Sciences4.8808 of 5 stars$53.14-1.0%$70.40+32.5%+25.8%$10.02B$2.83B-9.647,000RGENRepligen4.7941 of 5 stars$124.38+0.7%$172.83+39.0%-1.3%$6.99B$634.44M-276.401,778Positive NewsAnalyst DowngradeMDGLMadrigal Pharmaceuticals3.963 of 5 stars$302.64+0.6%$420.63+39.0%+8.0%$6.72B$317.38M-16.7790HALOHalozyme Therapeutics4.8462 of 5 stars$52.02-0.4%$61.90+19.0%-0.6%$6.41B$1.02B13.84390Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Repligen Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXEL) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
